ACB Stock Analysis: Buy, Sell, or Hold?
ACB - Aurora Cannabis Inc. Common Shares
$4.03
-0.02 (-0.49%)
▼
5d:
+0.75%
30d:
+43.42%
90d:
+17.84%
WAIT
LOW Confidence
Analysis Updated: Sep 2, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When ACB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ACB shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ACB shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ACB is currently trading at $4.03, which is considered extended relative to its 30-day fair value range of $2.94 to $3.99. From a valuation perspective, the stock is trading at a discount (Forward PE: -671.7) compared to its historical average (43.0). At these levels, the market is pricing in 0% annual earnings growth.
Technical Outlook: Technically, ACB is in a downtrend. The price is approaching resistance at $4.15. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ACB scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.23 (+54.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ACB is in a downtrend. The price is approaching resistance at $4.15. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ACB scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.23 (+54.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.94 -
$3.99
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
28.6%
Protect Your Profits
ACB is technically overbought (RSI 75). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (13/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 54.5% below Wall St target ($6.23)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.94 -
$3.99
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.75
Resistance Level
$4.15
Current Trend
Downtrend
Technical data as of
Sep 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-671.67
Wall Street Target
$6.23
(+54.5%)
Revenue Growth (YoY)
-8.8%
Earnings Growth (YoY)
-94.7%
Profit Margin
-38.2%
PE vs Historical
-671.7 vs 43.0
CHEAP
Share & Embed Analysis
Last updated: September 02, 2026 5:45 PM ET
Data refreshes hourly during market hours. Next update: 6:45 PM
Data refreshes hourly during market hours. Next update: 6:45 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 54 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 57 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 46 HOLD |
Advanced ACB Option Strategies
Professional options setups generated by AI based on today's ACB price and gamma walls.
